ATRC Projected Dividend Yield

AtriCure Inc ( NASDAQ : ATRC )

AtriCure provides treatments for atrial fibrillation (Afib), left atrial appendage management and post-operative pain. Co.'s ablation and left atrial appendage management products are used by physicians during both open-heart and minimally invasive procedures. Co.'s Isolator® Synergy™ Ablation System is approved by U.S. Food and Drug Administration (FDA) for the treatment of persistent and long-standing persistent Afib concomitant to other open-heart surgical procedures. The EPi-Sense® system is approved by FDA to treat patients with long-standing persistent Afib. All of Co.'s other ablation devices are cleared for sale in U.S., including its other radio frequency and cryoablation products.

20 YEAR PERFORMANCE RESULTS